MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine agonists"

  • 2018 International Congress

    Effectiveness of Rotigotine plus Intensive and Goal-based Rehabilitation versus Rotigotine alone in “de-novo” Parkinsonian subjects: A Randomized Controlled Trial with 18-month Follow-up

    D. Ferrazzoli, P. Ortelli, G. Riboldazzi, R. Maestri, G. Frazzitta (Gravedona ed Uniti, Italy)

    Objective: To evaluate the synergism between Dopamine Replacement Therapy (DRT) and rehabilitation in treating Parkinson's disease (PD), by investigating the short and the long-term effectiveness…
  • 2018 International Congress

    On Converting Patients From Oral Dopamine Agonists to the Carbidopa/Levodopa Enteral Suspension Method – Real World Conversion Ratios

    S. Nakano, L. Bahroo, F. Pagan, F. Amjad, S. Lo, I. Gambhir (Washington, D.C., DC, USA)

    Objective: To review guidelines for initiating Carbidopa/Levodopa Enteral Suspension method of delivery in the treatment of Parkinson’s Disease (PD) and to compare guidelines with real…
  • 2018 International Congress

    Effect of dopamine agonists versus levodopa as initial treatment in Parkinson’s Disease

    J. Chen, J. Hong, L. Chunfeng (Suzhou, China)

    Objective: We evaluated the efficacy of different starting drugs in the treatment of Parkinson's disease (PD), in order to further explore the initial therapy of…
  • 2018 International Congress

    Characteristics of dopaminergic treatments in advanced Parkinson’s before levodopa-carbidopa intestinal gel infusion: Data from 107 tested patients

    J. Szasz, V. Constantin, K. Orban-Kis, L. Bancu, D. Georgescu, J. Szederjesi, I. Mihaly, S. Szatmari (Tirgu Mures, Romania)

    Objective: To describe the characteristics of dopaminergic treatments in a large group of patients with advanced Parkinson’s Disease (APD) in which current non-invasive therapy (oral,…
  • 2018 International Congress

    The course of Parkinson’s disease in patients with impaired carbohydrate metabolism

    F. Akhmedova, B. Shagazatova, D. Artikova, F. Mirxaydarova (Tashkent, Uzbekistan)

    Objective: To study the state of lipid metabolism in PD patients with concomitant type 2diabetes (with different glucose tolerance and the effect of DA agonist…
  • 2018 International Congress

    Bdnf rs6265 and Other Variants Predict the Efficacy of Levodopa Monotherapy in Early-Stage Parkinson’s Disease

    C. Sortwell, P. Auinger, J. Goudreau, B. Pickut, M. Hacker, P. Charles, J. Lipton, A. Cole-Strauss, J. Elm, D. Fischer (Grand Rapids, MI, USA)

    Objective: To determine whether relatively prevalent variants in the gene for brain-derived neurotrophic factor (Bdnf) are associated with differential efficacy of levodopa or other dopaminergic…
  • 2018 International Congress

    Intranasal Delivery of Bromocriptine loaded Lipid Nano Carriers for Enhanced Brain Delivery in Parkinson’s disease

    S. V G, P. Vavia (Mumbai, India)

    Objective: The objective of this research work is to develop a lipid nanocarrier system of Bromocriptine and evaluate its increased efficacy in the management of…
  • 2018 International Congress

    Dopaminergic medication changes affect cognitive, mood, and quality of life outcomes after STN DBS

    D. Floden, O. Hogue, M. Saupe, R. Busch, K. Wilson, A. Ahmed (Cleveland, OH, USA)

    Objective: To determine whether there is a relationship between dopaminergic medication reduction and cognitive, mood, or quality of life outcomes after STN DBS for PD.…
  • 2018 International Congress

    The impact of a wearable device on Parkinson’s disease motor symptom management in patients starting rotigotine transdermal patch

    S. Isaacson, B. Boroojerdi, K. Klos, S. Carson, M. Markowitz, D. Heldman, M. Phillips, D. Terricabras, F. Woltering, D. Truong (Boca Raton, FL, USA)

    Objective: Open-label, multi-center pilot study (PD0049) to evaluate the impact of Kinesia 360 (an “at home” wearable device) on motor symptom management in Parkinson’s disease…
  • 2018 International Congress

    EEG microstates changes in response to increase in dopaminergic stimulation in treated typical Parkinson’s disease patients without clinical fluctuations

    V. Cortés, I. Serrano, N. Mendes, M. Del Castillo, A. Arroyo, J. Andreo, M. Del Valle, J. Herreros, JP. Romero, (Madrid, Spain)

    Objective: Neurotropic drugs may modulate Electroencephalography (EEG) microstates (MS), but there are no works showing EEG MS default-mode network changes in response to dopaminergic stimulation…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley